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Abstract
Nasopharyngeal aspirates, collected during outbreaks, of the
novel inﬂuenza A (H1N1) virus in Barcelona, were used to com-
pare the accuracy of a rapid antigen-based test (Binax) with the
real-time RT-PCR assay developed by the CDC. The sensitivity,
speciﬁcity and positive predictive value of the rapid test are
higher in patients less than 18 years old and during the acute
stage of the epidemic than in adult patients.
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Viral inﬂuenza is a seasonal infection associated with signiﬁ-
cant morbidity and mortality in both children and adults
[1,2] during local outbreaks or epidemics. Inﬂuenza viruses
infect, on average, 10–15% of the population annually. The
rapid detection of inﬂuenza viruses is important for the appli-
cation of preventive strategies and the initiatation of antiviral
therapy in patients at risk of complications. The recent
appearance and worldwide spread of the novel inﬂuenza A
(H1N1) virus [3,4] has highlighted the need to evaluate com-
mercially available rapid tests.
The aim of this study was to evaluate the BinaxNOW
Inﬂuenza A&B test (Binax, Inc., Portland, Maine, USA),
a rapid antigen-based test for detection of the novel swine-
origin inﬂuenza A (H1N1) virus, during outbreaks in a
tertiary-care hospital in Barcelona, Spain.
From June 2009 to October 2009, a total of 516 nasopha-
ryngeal aspirate specimens were collected. We included pae-
diatric and adult patients with suspected infection by
pandemic inﬂuenza A (H1N1) (inﬂuenza-like illness or pneu-
monia of unknown origin) who presented at the emergency
departments of Hospital Germans Trias i Pujol and required
hospitalization or suffered from an underlying disease that
indicated treatment according to criteria established by the
Inﬂuenza Commission of the hospital. Patients with any
immunodeﬁciency were included. Nasopharyngeal aspirates
of each patient were used immediately for testing or stored
at )80C.
The BinaxNOW Inﬂuenza A&B (Binax, Inc., Portland, ME,
USA) test is an immunochromatographic membrane assay that
uses highly sensitive monoclonal antibodies to detect inﬂuenza
type A and type B nucleoprotein antigens in nasopharyngeal
specimens. This test does not differentiate between novel
H1N1 and seasonal inﬂuenza A, but it provides a rapid
diagnosis of inﬂuenza A or B infection. The technique was per-
formed according to the manufacturer’s recommendations.
Total RNA was extracted using a commercial kit, the
QIAamp Viral RNA kit (Qiagen, Hilden, Germany), following
the manufacturer’s instructions. Viral RNA was extracted
from 200 lL of each sample. The RNA was used immedi-
ately in the following experiments or stored at )80C.
The presence of novel or seasonal inﬂuenza A virus was
conﬁrmed with the H1N1 assay of the CDC, approved by
the Food and Drug Administration. This Protocol includes a
panel of oligonucleotide primers and dual-labelled hydrolysis
(Taqman) probes to be used in real-time RT-PCR (rRT-PCR)
assays for the in vitro qualitative detection and characteriza-
tion of swine inﬂuenza viruses in respiratory specimens. The
InfA primer and probe set is designed for universal detection
of type A inﬂuenza viruses. The swInfA primer and probe set
is designed to speciﬁcally detect all swine inﬂuenza A viruses.
The swH1 primer and probe set is designed to speciﬁcally
detect novel inﬂuenza A (H1N1) 2009.
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Each clinical specimen was characterized by the Ct value
determined in the universal inﬂuenza type A rRT-PCR assay
with the matrix (M) gene used as the target [5]. Ct values
are indicators of the amount of virus in a specimen, with
lower values indicating higher viral titres.
The sensitivity, speciﬁcity, j index, positive predictive
value (PPV) and negative predictive value of the BinaxNOW
Inﬂuenza A&B test results as compared with those of the
rRT-PCR assay were calculated using standard formulas. The
calculations were performed with VassarStats tools (http://
faculty.vassar.edu/lowry/VassarStats.htm), and 95% CIs were
calculated for each value. Fisher’s exact test was performed
with the STATA 9.0 program (Stata Corp., College Station,
Texas, USA), and a p-value of <0.05 was considered to be
statistically signiﬁcant.
Informed consent was obtained from all patients and par-
ents of the children included.
Five hundred and sixteen samples of 499 patients were
studied with both techniques. The median age was 20 years
(range, 4 days to 87 years). There were 258 (52%) males.
Only four cases of seasonal inﬂuenza A were detected, and
they were not considered in the calculation. The period of
greatest percentage of H1N1-positive tests (33.8%) was from
16 October to 15 November. Inﬂuenza B was not detected
with the rapid test in any patient.
Among the 512 valid samples, 227 were rRT-PCR (CDC)-
positive. Of these, 137 were detected using the BinaxNOW
assay, corresponding to a sensitivity of 60.3%. The test
parameters are presented in Table 1. The PPV in patients
less than 18 years old was greater than in adult patients and
similar if it was considered only during the acute stage of the
epidemic.
The high PPV of the BinaxNOW assay observed in this
study indicates that positive results do not need to be con-
ﬁrmed by rRT-PCR. However, negative BinaxNOW results,
as well as negative results obtained with other rapid antigen
assays, should be conﬁrmed by rRT-PCR.
Various previous reports have described low sensitivity of
the BinaxNOW assay in comparison with rRT-PCR [5–7] for
detection of the novel inﬂuenza A (H1N1) virus. These
authors found the sensitivity of BinaxNOW to be in the
range of 11–40%. Unlike previous reports, our data show
high sensitivity and speciﬁcity for detection of the novel
inﬂuenza A (H1N1) virus using the BinaxNOW Inﬂuenza
A&B test. The high sensitivity of the test might be explained
by the study population, the majority of whom were children
(62%), who had more viral shedding, and also by the high
quality of specimen collection. Only nasopharyngeal aspirates,
and not swabs, were collected, and patients were selected
on the basis of high suspicion by expert clinicians. Further-
more, previous studies [5–7] considered small numbers of
patients.
Balish et al. [5] reported that the sensitivity of a rapid
diagnostic inﬂuenza test declines as the viral titre in the spec-
imen decreases. In agreement with these results, our ﬁndings
show that the sensitivity of the BinaxNOW assay declined
substantially with lower viral titres (determined by Ct val-
ues). Over cycle 27, the sensitivity dropped to 28% (Fisher’s
exact test, p 0.049).
This ﬁnding indicates that the BinaxNOW rapid antigen-
based test is highly sensitive and accurate for the detection of
inﬂuenza A virus (H1N1) in patients under 18 years of age,
and at any age during the most acute stage of an outbreak.
BinaxNOW could be an important tool for patient care,
because this test usually provides results within 30 min. This
might be especially important for hospitals with time con-
straints and limited funds to cover the expense of rRT-PCR.
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TABLE 1. Test parameters of the BinaxNOW Inﬂuenza A&B test as compared with the real-time RT-PCR (CDC) assay
Sensitivity Speciﬁcity PPV NPV j
Total samples 60.3 (53.6–66.7) 93.6 (90.0–96.1) 88.3 (82.0–92.7) 74.7 (69.8–79.1) 0.5584 (0.4844–0.6325)
Paediatric patients (£18 years) 65.3 (56.9–72.8) 96.4 (92.0–98.5) 94.1 (87.1–97.5) 76.1 (69.7–81.5) 0.6301 (0.5432–0.7170)
Adult patients (>18 years) 51.2 (39.8–62.4) 89.6 (82.2–94.3) 77.3 (63.4–87.2) 72.7 (64.5–79.6) 0.4317 (0.2975–0.5659)
Acute stage of infection 62.9 (54.9–70.3) 94.1 (87.1–97.5) 94.4 (87.8–97.7) 61.5 (53.3–69.1) 0.5198 (0.4195–0.6201)
PPV, positive predictive value; NPV, negative predictive value.
Sensitivity, speciﬁcity, PPV and NPV are given as % (95% CI).
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Abstract
Although neuraminidase inhibitors are active against most 2009–
2010 pandemic inﬂuenza A (H1N1) swine-origin strains, sporadic
cases of oseltamivir resistance have been described. Since April
2009, 54 cases of oseltamivir-resistant H1N1 swine-origin have
been reported in the USA (http://www.cdc.gov/ﬂu/weekly/;
accessed 1 February 2010). Approximately 1.4% of tested iso-
lates are oseltamivir resistant. We report a patient with an
underlying hematological malignancy who was hospitalized with
inﬂuenza A (H1N1) swine-origin and whose strain developed
oseltamivir resistance during therapy.
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A 26-year-old female with pre-B acute lymphocytic leukaemia
was admitted to our hospital on November 18, 2009 for
re-induction chemotherapy. She was started on high-dose
cytarabine, L-asparaginase, acyclovir and trimethoprim-sulpha-
methoxazole. On admission, her absolute neutrophil count
(ANC) was 800 cells/lL. On hospital day 3, she developed a
nonproductive cough and had a temperature of 102.6F with
an ANC of 300 cells/lL. She was started on vancomycin,
cefepime and oseltamivir 75 mg twice daily. One of two
blood cultures grew a-haemolytic streptococci. A nasopha-
ryngeal swab sent for respiratory viral panel testing (xTAG
RVP; Luminex Corp., Austin, TX, USA) revealed inﬂuenza A
(H1N1), nonsubtypeable probable swine-origin and rhinovi-
rus (Table 1). On hospital day 8, she had a temperature of
103.6F and posaconazole and meropenem were added, osel-
tamivir was continued, and cefepime was stopped. Chest
computed tomography (CT) demonstrated patchy airspace
disease in the right lung consistent with pneumonia. Fevers
continued and several blood and urine cultures were nega-
tive. A bronchoscopy performed on hospital day 11 revealed
negative cultures for aerobic, anaerobic, and acid-fast
TABLE 1. Inﬂuenza A (H1N1) testing
Hospital day
of specimen
collection
Specimen
source RVP assay Culture
H275Y
mutation
testinga
3 NP Inﬂuenza A H1N1,
swine-origin
Inﬂuenza A Negative
11 Bronchoscopy NA Inﬂuenza A Positive
17 NP Inﬂuenza A H1N1,
swine-origin
Inﬂuenza A Positive
20 NP Negative NA NA
NP, nasopharyngeal; NA, not available; RVP, respiratory viral panel.
aResistance testing performed on hospital day 17 returned on hospital day 23.
Isolates from hospital day 3 and 11 were subsequently tested for the H275Y
mutation (ViraCor, Lee’s Summit, MO, USA).
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